# Ivabradine

Drug · id `cardio:ivabradine` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Corlanor

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

Ivabradine, sold as Corlanor, is a medicine taken by mouth that the US label describes as a hyperpolarization-activated cyclic nucleotide-gated channel blocker, a drug that acts on a current in the natural pacemaker of the heart. The label read lists two uses: to reduce the risk of hospitalization for worsening heart failure in adults with stable, symptomatic chronic heart failure and a reduced left ventricular ejection fraction (35% or less, in sinus rhythm with a resting heart rate of 70 beats per minute or more, and already on the most beta-blocker they tolerate or unable to take one); and stable symptomatic heart failure due to dilated cardiomyopathy in children aged 6 months and older who are in sinus rhythm with an elevated heart rate.

## Technical summary

RxNorm ingredient 1649480; the label names the hydrochloride salt (RxNorm 1649479, UNII TP19837BZK, a broad match to the ingredient). MeSH D000077550 is Ivabradine. RxClass lists the FDA established pharmacologic class Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker; the atlas has no page for that class, so the record has no class parent. The label read is the Amgen Inc label for Corlanor, applications NDA206143 and NDA209964, effective 2026-11-09 in openFDA. Generic ivabradine labels were not read. The adult and pediatric statements sit in separate claims and contexts. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Children aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy, as described in the US label of Corlanor

Recipient: Child; Population: Pediatric patients aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy who are in sinus rhythm with an elevated heart rate, as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Pediatric patients aged 6 months and older, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Corlanor (ivabradine, Amgen Inc, applications NDA206143 and NDA209964; the version dated 2026-11-09 in openFDA) lists the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older who are in sinus rhythm with an elevated heart rate.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Pediatric patients aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy who are in sinus rhythm with an elevated heart rate, as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Pediatric patients aged 6 months and older, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says about pediatric patients. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The adult indication is recorded in a separate claim. The label's pediatric use, dosing and safety sections were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Corlanor (ivabradine tablets), Amgen Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 92018a65-38f6-45f7-91d4-a34921b81d0d (manufacturer Amgen Inc, application NDA206143 and NDA209964), returned on 2026-11-18. The label text is dated 2026-11-09 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2292018a65-38f6-45f7-91d4-a34921b81d0d%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.2 Heart Failure in Pediatric Patients. Retrieved 2026-11-18T17:27:13Z. Source state: Current. Version fingerprint: 88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d.
     How it applies: Label passage quoted in the research quote table (LB-08, and LB-10 for the sinus rhythm and heart rate condition).
  2. Background: openFDA drug label record for Corlanor (ivabradine tablets), Amgen Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 92018a65-38f6-45f7-91d4-a34921b81d0d (manufacturer Amgen Inc, application NDA206143 and NDA209964), returned on 2026-11-18. The label text is dated 2026-11-09 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2292018a65-38f6-45f7-91d4-a34921b81d0d%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T17:27:13Z. Source state: Current. Version fingerprint: 88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d.
     How it applies: Effective date of the label text read, 20261109.

## Context: Adults with stable, symptomatic chronic heart failure and reduced ejection fraction, as described in the US label of Corlanor

Recipient: Adult; Population: Adult patients with stable, symptomatic chronic heart failure with a left ventricular ejection fraction of 35% or less, in sinus rhythm with a resting heart rate of 70 beats per minute or more, who either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use, as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Corlanor (ivabradine, Amgen Inc, applications NDA206143 and NDA209964; the version dated 2026-11-09 in openFDA) describes ivabradine as a hyperpolarization-activated cyclic nucleotide-gated channel blocker. It lists reducing the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure whose left ventricular ejection fraction is 35% or lower, who are in sinus rhythm with a resting heart rate of 70 beats per minute or more and either are on maximally tolerated doses of beta-blockers or cannot take a beta-blocker.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adult patients with stable, symptomatic chronic heart failure with a left ventricular ejection fraction of 35% or less, in sinus rhythm with a resting heart rate of 70 beats per minute or more, who either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use, as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for in adults. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The pediatric use is in a separate claim. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Corlanor (ivabradine tablets), Amgen Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 92018a65-38f6-45f7-91d4-a34921b81d0d (manufacturer Amgen Inc, application NDA206143 and NDA209964), returned on 2026-11-18. The label text is dated 2026-11-09 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2292018a65-38f6-45f7-91d4-a34921b81d0d%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1. INDICATIONS AND USAGE. Retrieved 2026-11-18T17:27:13Z. Source state: Current. Version fingerprint: 88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for Corlanor (ivabradine tablets), Amgen Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 92018a65-38f6-45f7-91d4-a34921b81d0d (manufacturer Amgen Inc, application NDA206143 and NDA209964), returned on 2026-11-18. The label text is dated 2026-11-09 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2292018a65-38f6-45f7-91d4-a34921b81d0d%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Heart Failure in Adult Patients. Retrieved 2026-11-18T17:27:13Z. Source state: Current. Version fingerprint: 88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d.
     How it applies: Label passage quoted in the research quote table (LB-05, LB-06, LB-07).
  3. Background: openFDA drug label record for Corlanor (ivabradine tablets), Amgen Inc label: indications, mechanism, class (Regulator, edition The openFDA drug label record for set id 92018a65-38f6-45f7-91d4-a34921b81d0d (manufacturer Amgen Inc, application NDA206143 and NDA209964), returned on 2026-11-18. The label text is dated 2026-11-09 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2292018a65-38f6-45f7-91d4-a34921b81d0d%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T17:27:13Z. Source state: Current. Version fingerprint: 88339271a01e92bda6c7f7593d91fe219c336ce714748e5cc2c292f233414f5d.
     How it applies: Effective date of the label text read, 20261109.

## Connected pages

- FDA label lists reducing the risk of hospitalization for worsening heart failure in adults with chronic heart failure and a reduced left ventricular ejection fraction as an indication: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`) [a claim, not a settled fact; see claim `cardio:claim-fda-ivabradine-label-indications` and its context]
- FDA label lists stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients aged 6 months and older who are in sinus rhythm with an elevated heart rate as an indication: Dilated cardiomyopathy (`cardio:dilated-cardiomyopathy`) [a claim, not a settled fact; see claim `cardio:claim-fda-ivabradine-label-paediatric` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: fd6a76401d1c6b045926e2bdb33f9ea0baa0b32ac31673d19af645960e4b1dab
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
